{"id":4159,"date":"2019-08-13T08:26:00","date_gmt":"2019-08-13T08:26:00","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=4159"},"modified":"2021-08-02T08:10:45","modified_gmt":"2021-08-02T08:10:45","slug":"asprees-australian-award-trifecta","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/asprees-australian-award-trifecta\/","title":{"rendered":"ASPREE&#8217;s Australian award trifecta"},"content":{"rendered":"\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<div id=\"toc_container\" class=\"no_bullets\"><ul class=\"toc_list\"><li><a href=\"#Impact_of_ASPREE_trial_on_public_health_recognised\">Impact of ASPREE trial on public health recognised<\/a><\/li><li><a href=\"#Monash_University_Deans_Award_Faculty_of_Medicine_Nursing_and_Health_Sciences\">Monash University Dean\u2019s Award (Faculty of Medicine, Nursing and Health Sciences)<\/a><\/li><li><a href=\"#Australian_Clinical_Trial_Alliance_Clinical_Trial_of_the_Year\">Australian Clinical Trial Alliance \u2013 Clinical Trial of the Year<\/a><\/li><li><a href=\"#Alfred_Research_Alliance_Highest_Impact_Factor\">Alfred Research Alliance \u2013 Highest Impact Factor<\/a><\/li><\/ul><\/div>\n<h2 class=\"wp-block-heading\"><span id=\"Impact_of_ASPREE_trial_on_public_health_recognised\">Impact of ASPREE trial on public health recognised<\/span><\/h2>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>We are pleased to share three Australian research accolades recently awarded to the <a href=\"\/aus\/aspree-publishes-trial-results-in-new-england-journal-of-medicine-today\/\">ASPREE clinical trial<\/a> for its significance to public health. ASPREE team acknowledged the contribution of <a href=\"\/aus\/for-participants\/\">participants<\/a>, <a href=\"\/aus\/for-clinicians\/\">GPs<\/a> and fellow <a href=\"\/aus\/about-us\/\">team members<\/a> to the world-first trial.<\/p>\r\n\r\n\r\n\r\n<p>The three awards are:<\/p>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\"><span id=\"Monash_University_Deans_Award_Faculty_of_Medicine_Nursing_and_Health_Sciences\">Monash University Dean\u2019s Award (Faculty of Medicine, Nursing and Health Sciences)<\/span><\/h3>\r\n\r\n\r\n\r\n<p>The Dean\u2019s award recognised the impact of ASPREE on the healthcare of our ageing population. Despite the widespread use of aspirin, before ASPREE, no trial had adequately supported its use for primary prevention in healthy older adults. Use was based on secondary prevention studies (i.e. after a heart attack) and on a few primary prevention studies in mostly middle-aged adults.<\/p>\r\n\r\n\r\n\r\n<div class=\"wp-block-image\">\r\n<figure class=\"aligncenter size-large is-resized\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-4166\" src=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JL-SO-SF-RT-Deans-award-5.08.2019resize-1024x660-1.jpg\" alt=\"Woman with blond hair accepts a certificate and shakes the presenter's hand. Standing alongside are three women, all senior managers working on the ASPREE trial.\" width=\"983\" height=\"633\" srcset=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JL-SO-SF-RT-Deans-award-5.08.2019resize-1024x660-1.jpg 983w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JL-SO-SF-RT-Deans-award-5.08.2019resize-1024x660-1-980x632.jpg 980w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JL-SO-SF-RT-Deans-award-5.08.2019resize-1024x660-1-480x309.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 983px, 100vw\" \/>\r\n<figcaption><em>Above: accepting the Award for Research Impact from left, Dr Jessica Lockery, Dr Suzanne Orchard, Dr Sharyn Fitzgerald, Dr Ruth Trevaks. Absent: ASPREE Executive Director, Associate Professor Robyn Woods<\/em>.<\/figcaption>\r\n<\/figure>\r\n<\/div>\r\n\r\n\r\n\r\n<p>In March 2019, citing the results of the ASPREE trial (published only six months prior), the American College of Cardiology and American Heart Association (ACC\/AHA) jointly <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S073510971933877X?via%3Dihub\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>published<\/strong> <\/a>updated guidelines in which they recommended\u00a0<a href=\"https:\/\/www.heart.org\/en\/news\/2019\/03\/18\/avoid-daily-aspirin-unless-your-doctor-prescribes-it-new-guidelines-advise\">against<\/a> routine use of low-dose aspirin for primary prevention of cardiovascular disease in healthy elderly adults.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\"><span id=\"Australian_Clinical_Trial_Alliance_Clinical_Trial_of_the_Year\">Australian Clinical Trial Alliance \u2013 Clinical Trial of the Year<\/span><\/h3>\r\n\r\n\r\n\r\n<div class=\"wp-block-image\">\r\n<figure class=\"aligncenter size-large is-resized\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-4167\" src=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/016-TrialoftheYear2019-20May19-20May19-1024x683-1.jpg\" alt=\"A group of ASPREE researchers and participants stand together at the ACTA Clinical Trial of the Year Award ceremony\" width=\"997\" height=\"666\" srcset=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/016-TrialoftheYear2019-20May19-20May19-1024x683-1.jpg 997w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/016-TrialoftheYear2019-20May19-20May19-1024x683-1-980x654.jpg 980w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/016-TrialoftheYear2019-20May19-20May19-1024x683-1-480x320.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 997px, 100vw\" \/>\r\n<figcaption><em>Above: Representatives from the ASPREE team attended the ACTA award for Clinical Trial of the Year ceremony, along with three ASPREE participants and Executive Director, Assoc. Prof. Robyn Woods (blue jacket, centre).\u00a0 ASPREE participant Prof Bruce Holloway shared his experience of being in the trial at the event.<\/em><\/figcaption>\r\n<\/figure>\r\n<\/div>\r\n\r\n\r\n\r\n<p>On the 20th May (International Clinical Trials Day), the <a href=\"https:\/\/clinicaltrialsalliance.org.au\/latest-news\/trial-of-the-year-awards\/\" target=\"_blank\" rel=\"noopener noreferrer\">Australian Clinical Trial Alliance (ACTA)<\/a> awarded ASPREE with the inaugural \u2018Clinical Trial of the Year\u2019 for its significant contribution to the health of older people around the world.<br \/>Executive Director, Associate Prof Robyn Woods, accepted the award on behalf of ASPREE, acknowledging the contribution from ASPREE participants, GPs and the research team and support staff to the trial.<br \/>\u201cASPREE was a huge undertaking that is already seeing real impact in the community, with millions of older people around the world without a clinical need to take aspirin, now able to take one less daily medication,\u201d she said.<\/p>\r\n\r\n\r\n\r\n<p>ACTA Chair, Prof John Zalcberg said, \u201cClinical trials are vital to ensuring patients receive the best treatments and get the best outcomes. Effective and efficient treatments not only reduce suffering they can also mean less time spent receiving treatment and less money spent by the patient and the health system.\u201d<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\"><span id=\"Alfred_Research_Alliance_Highest_Impact_Factor\">Alfred Research Alliance \u2013 Highest Impact Factor<\/span><\/h3>\r\n\r\n\r\n\r\n<p>The following month,\u00a0 ASPREE\u2019s Principal Investigator in Australia, Prof John McNeil (pictured below), accepted the Alfred Research Alliance award for highest impact factor publications. ASPREE was a gold standard clinical trial and of such significance to older adults and doctors that the prestigious <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1800722\" target=\"_blank\" rel=\"noopener noreferrer\">New England Journal of Medicine<\/a> took the unusual step of publishing three ASPREE papers at the same time.<\/p>\r\n\r\n\r\n\r\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-4168\" src=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JM-Alfred-Research-Alliance-Award1024x770.jpg\" alt=\"A grey haired man stands at a lectern with images of three ASPREE papers published in the New England Journal of Medicine projected on the screen behind him.\" width=\"1011\" height=\"760\" srcset=\"https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JM-Alfred-Research-Alliance-Award1024x770.jpg 1011w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JM-Alfred-Research-Alliance-Award1024x770-980x737.jpg 980w, https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2021\/02\/JM-Alfred-Research-Alliance-Award1024x770-480x361.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1011px, 100vw\" \/>\r\n<figcaption><em>Above: ASPREE Principal Investigator in Australia, Prof John McNeil, accepted the the Alfred Research Alliance award for highest impact factor publications on behalf of the ASPREE team. <\/em><\/figcaption>\r\n<\/figure>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>ASPREE accepts three major awards in recognition of the primary prevention aspirin trial&#8217;s major contribution to public health.<\/p>\n","protected":false},"author":2,"featured_media":4163,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,18,16],"tags":[28,73,88,74],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4159"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=4159"}],"version-history":[{"count":19,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4159\/revisions"}],"predecessor-version":[{"id":8291,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4159\/revisions\/8291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media\/4163"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=4159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=4159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=4159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}